Skip to main content
Top
Published in: Breast Cancer Research 3/2007

01-06-2007 | Editorial

Identification of women with an increased risk of developing radiation-induced breast cancer

Authors: Elisabeth Cardis, Janet Hall, Sean V Tavtigian

Published in: Breast Cancer Research | Issue 3/2007

Login to get access

Abstract

In the previous issue of Breast Cancer Research, Broeks and collaborators present the results of a study suggesting that germline mutations in BRCA1, BRCA2, ATM or CHEK2 may double the risk of radiation-induced contralateral breast cancer following radiotherapy for a first breast cancer. The assocation appeared to be strongest among women who were below the age of 40 at the time of their first breast cancer and among women who developed their second cancer 5 years or more after the first. While there were a number of methodological issues that might limit the conclusions drawn from this paper, this is one of several recent studies suggesting that carriers of pathogenic alleles in DNA repair and damage recognition genes may have an increased risk of breast cancer following exposure to ionising radiation, even at low doses. This finding has important implications for the protection of breast cancer patients and their close relatives. If confirmed, mutation carriers may wish to consider alternatives to X-ray for diagnostic purposes. The need for tailored cancer treatment strategies in carriers should also be evaluated carefully.
Literature
1.
go back to reference Ferlay J, Bray F, Pisani P, Parkin DM, eds: GLOBOCAN 2000: Cancer Incidence and Mortality Worldwide. 2001, Lyon: IARC Cancer Base No 5 Ferlay J, Bray F, Pisani P, Parkin DM, eds: GLOBOCAN 2000: Cancer Incidence and Mortality Worldwide. 2001, Lyon: IARC Cancer Base No 5
2.
go back to reference Ronckers CM, Erdmann CA, Land CE: Radiation and breast cancer: a review of current evidence. Breast Cancer Res. 2005, 7: 21-32. 10.1186/bcr970.CrossRefPubMed Ronckers CM, Erdmann CA, Land CE: Radiation and breast cancer: a review of current evidence. Breast Cancer Res. 2005, 7: 21-32. 10.1186/bcr970.CrossRefPubMed
3.
go back to reference UNSCEAR: Sources and Effects of Ionizing Radiation. Sources. 2000, New York; UNSCEAR, 1: UNSCEAR: Sources and Effects of Ionizing Radiation. Sources. 2000, New York; UNSCEAR, 1:
4.
go back to reference Walsh T, King MC: Ten genes for inherited breast cancer. Cancer Cell. 2007, 11: 103-105. 10.1016/j.ccr.2007.01.010.CrossRefPubMed Walsh T, King MC: Ten genes for inherited breast cancer. Cancer Cell. 2007, 11: 103-105. 10.1016/j.ccr.2007.01.010.CrossRefPubMed
5.
go back to reference Andrieu N, Easton D, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Peock S, EMBRACE, Noguès C, et al: Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the IBCCS Study. J Clin Oncol. 2006, 24: 3361-3366. 10.1200/JCO.2005.03.3126.CrossRefPubMed Andrieu N, Easton D, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Peock S, EMBRACE, Noguès C, et al: Low-dose ionizing radiation significantly increases the risk of breast cancer among BRCA1/2 mutation carriers in the IBCCS Study. J Clin Oncol. 2006, 24: 3361-3366. 10.1200/JCO.2005.03.3126.CrossRefPubMed
6.
go back to reference Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R, Olson ER, Wolitzer AL, Seminara D, Whittemore AS, et al: The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2006, 15: 348-352. 10.1158/1055-9965.EPI-05-0557.CrossRefPubMed Bernstein JL, Teraoka SN, John EM, Andrulis IL, Knight JA, Lapinski R, Olson ER, Wolitzer AL, Seminara D, Whittemore AS, et al: The CHEK2*1100delC allelic variant and risk of breast cancer: screening results from the Breast Cancer Family Registry. Cancer Epidemiol Biomarkers Prev. 2006, 15: 348-352. 10.1158/1055-9965.EPI-05-0557.CrossRefPubMed
7.
go back to reference Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, van Leeuwen FE, et al: Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007, 9: R26-10.1186/bcr1668.CrossRefPubMedPubMedCentral Broeks A, Braaf LM, Huseinovic A, Nooijen A, Urbanus J, Hogervorst FB, Schmidt MK, Klijn JG, Russell NS, van Leeuwen FE, et al: Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study. Breast Cancer Res. 2007, 9: R26-10.1186/bcr1668.CrossRefPubMedPubMedCentral
8.
go back to reference Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, et al: Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003, 72: 1023-1028. 10.1086/373965.CrossRefPubMedPubMedCentral Schutte M, Seal S, Barfoot R, Meijers-Heijboer H, Wasielewski M, Evans DG, Eccles D, Meijers C, Lohman F, Klijn J, et al: Variants in CHEK2 other than 1100delC do not make a major contribution to breast cancer susceptibility. Am J Hum Genet. 2003, 72: 1023-1028. 10.1086/373965.CrossRefPubMedPubMedCentral
9.
go back to reference Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, van't Veer LJ: The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2007 Mar 28; doi: 10.1007/s10549-007-9543-6 Broeks A, Braaf LM, Huseinovic A, Schmidt MK, Russell NS, van Leeuwen FE, Hogervorst FB, van't Veer LJ: The spectrum of ATM missense variants and their contribution to contralateral breast cancer. Breast Cancer Res Treat. 2007 Mar 28; doi: 10.1007/s10549-007-9543-6
10.
go back to reference Tischkowitz MD, Foulkes WD: The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006, 5: 963-967.CrossRefPubMed Tischkowitz MD, Foulkes WD: The basal phenotype of BRCA1-related breast cancer: past, present and future. Cell Cycle. 2006, 5: 963-967.CrossRefPubMed
11.
go back to reference Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, et al: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMed Frank TS, Manley SA, Olopade OI, Cummings S, Garber JE, Bernhardt B, Antman K, Russo D, Wood ME, Mullineau L, et al: Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998, 16: 2417-2425.PubMed
12.
go back to reference Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002, 20: 1480-1490. 10.1200/JCO.20.6.1480.CrossRefPubMed Frank TS, Deffenbaugh AM, Reid JE, Hulick M, Ward BE, Lingenfelter B, Gumpper KL, Scholl T, Tavtigian SV, Pruss DR, et al: Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002, 20: 1480-1490. 10.1200/JCO.20.6.1480.CrossRefPubMed
13.
go back to reference Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002, 359: 1471-1477. 10.1016/S0140-6736(02)08434-9.CrossRefPubMed Haffty BG, Harrold E, Khan AJ, Pathare P, Smith TE, Turner BC, Glazer PM, Ward B, Carter D, Matloff E, et al: Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet. 2002, 359: 1471-1477. 10.1016/S0140-6736(02)08434-9.CrossRefPubMed
Metadata
Title
Identification of women with an increased risk of developing radiation-induced breast cancer
Authors
Elisabeth Cardis
Janet Hall
Sean V Tavtigian
Publication date
01-06-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 3/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1733

Other articles of this Issue 3/2007

Breast Cancer Research 3/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine